NCT00775606 - Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

January 31, 2011

Conditions

Acquired Immune Deficiency Syndrome

Interventions

DRUG

Lopinavir 400 mg/ritonavir 100 mg

Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD

DRUG

Efavirenz

Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD

Trial Locations (4)

Rush University Medical Center, Chicago

University of Illinois Medical Center, Chicago

Howard Brown Health Center, Chicago

University of Chicago Hospital, Chicago